<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469040</url>
  </required_header>
  <id_info>
    <org_study_id>B2C108784</org_study_id>
    <nct_id>NCT00469040</nct_id>
  </id_info>
  <brief_title>Safety, Blood Levels and Effects of GW642444</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Parallel-group, 14 Day Repeat Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Extra-pulmonary Pharmacodynamics of Inhaled Doses of GW642444M Formulated With Magnesium Stearate in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      GW642444 (the study medicine) is a new experimental medicine for treating asthma and chronic
      obstructive pulmonary disease (COPD). People with asthma and COPD suffer from breathlessness
      because the small tubes (bronchioles) that carry air in and out of the lungs become narrow.
      We hope that the study medicine will work by relaxing the muscles in the airways and help to
      keep the airways open, and make breathing easier. The study medicine might improve on
      available treatments by having fewer side-effects, and by working faster and for longer, so
      that patients could take it once daily, instead of twice daily.

      When a medicine is made into a form ready to be given to patients, inactive ingredients are
      often added. Inactive ingredients might be used to help a medicine work better, to make it
      easier to produce the medicine, or to make it easier to get an accurate dose of medicine. In
      this study, the study medicine contains the inactive ingredient magnesium stearate.

      We need to check that the study medicine doesn't cause problems when inhaled along with
      magnesium stearate. So, we're doing this study in healthy people to find out the answers to
      these questions.

      1)Do repeated once-daily doses of the study medicine cause any important side effects when
      inhaled, along with magnesium stearate, as a fine powder? 2)How much of the study medicine
      gets into the bloodstream and how long does the body take to get rid of it?
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 28, 2007</start_date>
  <completion_date type="Actual">April 16, 2007</completion_date>
  <primary_completion_date type="Actual">April 16, 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>General safety and tolerability as measured by ECG, blood pressure, pulse rate and blood and urine tests. Repeated measures on Day 1, 7 and 14</measure>
    <time_frame>Repeated measures on Day 1, 7 and 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of the medicine on the body as measured by potassium and glucose levels in the blood. Monitoring of the study medicine in the body by analysis of blood samples. Repeated measures on Day 1, 7 and 14</measure>
    <time_frame>Repeated measures on Day 1, 7 and 14</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>GW642444M 25mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Cohort 1 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 25 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GW642444M 50mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects after randomization will receive two inhalations of 25 mcg GW642444M in Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GW642444M 100mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Cohort 2 if subjects meet the stopping criteria the dose of GW642444M will changed to one inhalation of 100 mcg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GW642444M 200mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects after randomization will receive two inhalations of 100 mcg GW642444M in Cohort 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GW642444M 400mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects after randomization will receive two inhalations of 200 mcg GW642444M in Cohort 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW642444M for 14 days</intervention_name>
    <description>M salt</description>
    <arm_group_label>GW642444M 25mcg</arm_group_label>
    <arm_group_label>GW642444M 400mcg</arm_group_label>
    <arm_group_label>GW642444M 100mcg</arm_group_label>
    <arm_group_label>GW642444M 50mcg</arm_group_label>
    <arm_group_label>GW642444M 200mcg</arm_group_label>
    <other_name>GW642444 (25</other_name>
    <other_name>50</other_name>
    <other_name>100</other_name>
    <other_name>200 &amp; 400 mcg) for 14 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  healthy males and females (of non-childbearing potential) aged 18-55

          -  body weight &gt;50kg with BMI 19-29.9 kg/m2

          -  normal ECG recording

          -  non-smoker

        Exclusion criteria:

          -  high blood pressure (above 140/90 mmHg)

          -  pulse outside range 45 - 90 bpm

          -  history of breathing problems e.g. asthma

          -  low haemoglobin (&lt;11 g/dL)

          -  blood donation within 56 days of study start

          -  taking regular medication

          -  participation in another trial within 4 months of study start

          -  history of drug or alcohol abuse

          -  abnormal clinical laboratory tests

          -  known allergies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7NS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <link>
    <url>https://www.gsk-clinicalstudyregister.com/study/B2C108784?search=study&amp;search_terms=B2C108784#rs</url>
    <description>Results for study B2C108784 can be found on the GSK Clinical Study Register.</description>
  </link>
  <reference>
    <citation>Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013 Apr;26(2):256-64. doi: 10.1016/j.pupt.2012.12.001. Epub 2012 Dec 8.</citation>
    <PMID>23232038</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2007</study_first_posted>
  <last_update_submitted>August 2, 2017</last_update_submitted>
  <last_update_submitted_qc>August 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GW642444,</keyword>
  <keyword>healthy subjects</keyword>
  <keyword>magnesium stearate,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>B2C108784</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C108784</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C108784</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C108784</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C108784</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C108784</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C108784</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

